Zydus Lifesciences Ltd has bagged final approval from the US Food and Drug Administration (USFDA) to produce and market Dasatinib tablets in the US. The approved strengths are 20 mg, 50 mg, 70 mg ...

Zydus Lifesciences Ltd on Wednesday said it received final approval from the United States Food and Drug Administration (USFDA) to manufacture Dasatinib tablets in 20 mg, 50 mg, 70 mg, 80 mg, 100 ...

The Delhi High Court has granted an interim injunction against Zydus Lifesciences, an Ahmedabad-based drug maker, following a ...

Zydus Lifesciences share price gained more than 3 percent in the early trade on March 6 after the company received final approval from USFDA for Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 ...

Under the deal, Zydus will purchase certain Agenus facilities in Emeryville, Calif., and Berkeley, Calif., for $75 million. India-based Zydus will use these facilities as their flagship U.S. sites ...

LEXINGTON, Mass., June 03, 2025--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd ...

Zydus, which plans to leverage the U.S. facilities to launch its BioCDMO business, will also shell out about $16 million to acquire an estimated 2.1 million shares of Agenus at $7.50 per share.

Retrospective study finds that cancer drug also lowers blood glucose Date: November 9, 2021 Source: Mayo Clinic Summary: Dasatinib, a drug that often is used to treat certain types of leukemia ...

Nature Reviews Clinical Oncology - Dasatinib is active in imatinib-resistant and imatinib-intolerant patients with CML Skip to main content Thank you for visiting nature.com.